{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:00Z","timestamp":1792097340383,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["UL1TR0002378"],"award-info":[{"award-number":["UL1TR0002378"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["TR002382"],"award-info":[{"award-number":["TR002382"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["P 30CA138292"],"award-info":[{"award-number":["P 30CA138292"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-24-1258662-01-IBCD"],"award-info":[{"award-number":["PF-24-1258662-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR002382"],"award-info":[{"award-number":["TR002382"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR0002378"],"award-info":[{"award-number":["UL1TR0002378"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA266088"],"award-info":[{"award-number":["R21CA266088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA287866"],"award-info":[{"award-number":["R01CA287866"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228406"],"award-info":[{"award-number":["R01CA228406"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218233","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:51:21Z","timestamp":1766508681000},"page":"218233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A phase Ib\/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling"],"prefix":"10.1016","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-8132","authenticated-orcid":false,"given":"Natalie K.","family":"Horvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-4977","authenticated-orcid":false,"given":"Ashley","family":"McCook-Veal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-1461","authenticated-orcid":false,"given":"Erin E.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":false,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumide","family":"Gbolahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deon","family":"Doxie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Herting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacklyn","family":"Hammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Switchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystal M.","family":"Paulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-5746","authenticated-orcid":false,"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-7678","authenticated-orcid":false,"given":"Gregory B.","family":"Lesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2025.218233_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.canlet.2025.218233_bib2","first-page":"12","article-title":"CA: a cancer J Clin","volume":"74","author":"Siegel","year":"2024","journal-title":"2024"},{"issue":"11","key":"10.1016\/j.canlet.2025.218233_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218233_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218233_bib5","doi-asserted-by":"crossref","first-page":"688377","DOI":"10.3389\/fonc.2021.688377","article-title":"The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.218233_bib6","first-page":"24","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218233_bib7","article-title":"Advances in the management of pancreatic cancer","volume":"383","author":"Chiaro","year":"2023","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.canlet.2025.218233_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218233_bib9","doi-asserted-by":"crossref","first-page":"1436973","DOI":"10.3389\/fimmu.2024.1436973","article-title":"HSP90 multi-functionality in cancer","volume":"15","author":"Albakova","year":"2024","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.canlet.2025.218233_bib10","doi-asserted-by":"crossref","first-page":"15968","DOI":"10.1021\/acs.jmedchem.4c00966","article-title":"Targeting HSP90 for cancer therapy: current progress and emerging prospects","volume":"67","author":"Liang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chembiol.2020.10.005","article-title":"HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins","volume":"28","author":"Zavareh","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2025.218233_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10456-013-9373-6","article-title":"Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1\u03b1 and STAT-3","volume":"16","author":"Nagaraju","year":"2013","journal-title":"Angiogenesis"},{"issue":"22","key":"10.1016\/j.canlet.2025.218233_bib13","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/1078-0432.CCR-18-0565","article-title":"Combined BRAF and HSP90 inhibition in patients with unresectable BRAFV600E-Mutant melanoma","volume":"24","author":"Eroglu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218233_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1535-7163.MCT-19-0911","article-title":"Heat shock Protein-90 inhibition alters activation of pancreatic stellate cells and enhances the efficacy of PD-1 blockade in pancreatic cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"13","key":"10.1016\/j.canlet.2025.218233_bib15","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-12-0538","article-title":"Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells","volume":"72","author":"Rao","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218233_bib16","doi-asserted-by":"crossref","first-page":"2475620","DOI":"10.1080\/2162402X.2025.2475620","article-title":"XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib\/II clinical trial","volume":"14","author":"Phillips","year":"2025","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218233_bib18","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.12688\/f1000research.16866.2","article-title":"Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS \u00ae macros","volume":"7","author":"Liu","year":"2019","journal-title":"F1000Research"},{"issue":"12","key":"10.1016\/j.canlet.2025.218233_bib19","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1080\/21645515.2021.2003645","article-title":"Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 And\/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy","volume":"17","author":"Ota","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"issue":"9","key":"10.1016\/j.canlet.2025.218233_bib20","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1038\/cti.2017.43","article-title":"Regulatory T-cell heterogeneity and the cancer immune response","volume":"6","author":"Ward-Hartstonge","year":"2017","journal-title":"Clin Transl Immunol"},{"issue":"7","key":"10.1016\/j.canlet.2025.218233_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/jcm7070172","article-title":"Tumor B7-H3 (CD276) expression and survival in pancreatic cancer","volume":"7","author":"Inamura","year":"2018","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3892\/ijmm.2012.1212","article-title":"B7-H3 overexpression in pancreatic cancer promotes tumor progression","volume":"31","author":"Zhao","year":"2012","journal-title":"Int. J. Mol. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.218233_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12032-024-02361-1","article-title":"CTLA-4 silencing could promote anti-tumor effects in hepatocellular","volume":"41","author":"Mardi","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2025.218233_bib24","doi-asserted-by":"crossref","first-page":"608024","DOI":"10.3389\/fimmu.2020.608024","article-title":"Beyond T-Cells: functional characterization of CTLA-4 expression in immune and non-immune cell types","volume":"11","author":"Oyewole-Said","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib25","first-page":"9","article-title":"IL-1-induced JAK\/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","author":"Biffi","year":"2018","journal-title":"Cancer Discov."},{"issue":"0","key":"10.1016\/j.canlet.2025.218233_bib26","first-page":"8","article-title":"The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma","author":"Diab","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2025.218233_bib28","doi-asserted-by":"crossref","first-page":"860767","DOI":"10.3389\/fonc.2022.860767","article-title":"Intra-tumoral CD8+ T-Cell infiltration and PD-L1 positivity in homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"12","author":"Golesworthy","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/diagnostics12020294","article-title":"Evaluation of MMR status and PD-L1 expression using specimens obtained by EUS-FNB in patients with pancreatic ductal adenocarcinoma (PDAC)","volume":"12","author":"Constantin","year":"2022","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.canlet.2025.218233_bib30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.218233_bib31","doi-asserted-by":"crossref","first-page":"113012","DOI":"10.1016\/j.isci.2025.113012","article-title":"Primary and metastatic cellular landscapes in human pancreatic cancer","volume":"28","author":"Steele","year":"2025","journal-title":"iScience"},{"issue":"15","key":"10.1016\/j.canlet.2025.218233_bib32","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2025.218233_bib33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/mc.22185","article-title":"Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer","volume":"54","author":"Nagaraju","year":"2015","journal-title":"Mol. Carcinog."},{"issue":"20","key":"10.1016\/j.canlet.2025.218233_bib34","doi-asserted-by":"crossref","first-page":"9980","DOI":"10.18632\/oncotarget.2484","article-title":"HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy","volume":"5","author":"Nagaraju","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.canlet.2025.218233_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/2326-6066.CIR-15-0057","article-title":"Targeting heat-shock protein 90 (HSP90) as a complementary strategy to immune checkpoint blockade for cancer therapy","volume":"3","author":"Proia","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.218233_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"issue":"5","key":"10.1016\/j.canlet.2025.218233_bib37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mdv031","article-title":"Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer\u2014results of a first-in-man dose-escalation study with a fixed-dose extension phase","volume":"26","author":"Isambert","year":"2015","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218233_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003125","article-title":"Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma","volume":"9","author":"Lau","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.canlet.2025.218233_bib39","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3390\/cells11162556","article-title":"Targeting heat-shock protein 90 in cancer: an update on combination therapy","volume":"11","author":"Ren","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.canlet.2025.218233_bib40","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1007\/s00432-023-04689-z","article-title":"Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?\u2014A systematic review","volume":"149","author":"Magyar","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218233_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/73d83e95-8f14-48ed-bb67-2310a33e4ecc","article-title":"High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888","volume":"6","author":"Lyman","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.canlet.2025.218233_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cstres.2024.08.002","article-title":"Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials","volume":"29","author":"Chang","year":"2024","journal-title":"Cell Stress Chaperones"},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cells12020277","article-title":"The distinct assignments for Hsp90\u03b1 and Hsp90\u03b2: more than skin deep","volume":"12","author":"Chang","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.canlet.2025.218233_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/mcb.00459-21","article-title":"Heterogeneous responses and isoform compensation dim the therapeutic window of Hsp90 ATP-binding inhibitors in cancer","volume":"42","author":"Tang","year":"2022","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218233_bib45","article-title":"High-dimensional protein analysis uncovers distinct immunological and stromal features in primary and metastatic pancreatic ductal adenocarcinoma","author":"Greene","year":"2025","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525008055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525008055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:15Z","timestamp":1792096935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525008055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"alternative-id":["S0304383525008055"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218233","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib\/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218233"}}